Silk Road Medical, Inc
NASDAQ:SILK
27.49 (USD) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Revenue
| 177.134 | 138.638 | 101.475 | 75.227 | 63.354 | 34.557 | 14.258 |
Cost of Revenue
| 50.048 | 37.876 | 25.446 | 21.291 | 15.927 | 10.874 | 5.129 |
Gross Profit
| 127.086 | 100.762 | 76.029 | 53.936 | 47.427 | 23.683 | 9.129 |
Gross Profit Ratio
| 0.717 | 0.727 | 0.749 | 0.717 | 0.749 | 0.685 | 0.64 |
Reseach & Development Expenses
| 41.324 | 36.449 | 27.11 | 21.271 | 12.272 | 10.258 | 7.242 |
General & Administrative Expenses
| 144.572 | 115.97 | 96.166 | 75.33 | 62.858 | 34.82 | 20.261 |
Selling & Marketing Expenses
| 0.461 | 0.347 | 0.221 | 0.194 | 0.362 | 0.186 | 0.218 |
SG&A
| 145.033 | 116.317 | 96.387 | 75.524 | 63.22 | 34.82 | 20.261 |
Other Expenses
| 0.442 | -0.19 | -0.023 | -0.08 | -21.054 | -12.063 | 2.927 |
Operating Expenses
| 186.357 | 152.766 | 123.497 | 96.795 | 75.492 | 45.078 | 27.503 |
Operating Income
| -59.271 | -52.004 | -47.468 | -42.859 | -28.065 | -21.395 | -18.374 |
Operating Income Ratio
| -0.335 | -0.375 | -0.468 | -0.57 | -0.443 | -0.619 | -1.289 |
Total Other Income Expenses Net
| 3.528 | -3.006 | -2.343 | -4.506 | -24.35 | -12.063 | 2.927 |
Income Before Tax
| -55.743 | -55.01 | -49.811 | -47.365 | -52.415 | -37.63 | -19.356 |
Income Before Tax Ratio
| -0.315 | -0.397 | -0.491 | -0.63 | -0.827 | -1.089 | -1.358 |
Income Tax Expense
| 0.043 | 3.006 | 0.576 | 3.02 | 3.658 | -11.874 | 6.87 |
Net Income
| -55.743 | -58.016 | -50.387 | -50.385 | -56.073 | -37.629 | -19.356 |
Net Income Ratio
| -0.315 | -0.418 | -0.497 | -0.67 | -0.885 | -1.089 | -1.358 |
EPS
| -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.8 |
EPS Diluted
| -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.8 |
EBITDA
| -55.479 | -49.667 | -47.293 | -41.755 | -26.409 | -32.752 | -15.284 |
EBITDA Ratio
| -0.313 | -0.358 | -0.466 | -0.555 | -0.417 | -0.948 | -1.072 |